Aurigene Discovery Technologies Limited
39-40, KIADB Industrial Area
Electronic City Phase II, Hosur Road
Email: partnerships@aurigene. com
27 articles with Aurigene Discovery Technologies Limited
Aurigene Discovery Technologies Limited Announces Drug Discovery, Development and Commercialization Partnership with EQRx
The collaboration combines Aurigene’s small molecule drug discovery platform and EQRx's pioneering business model to accelerate the development of drug candidates in the areas of oncology and immune-inflammatory diseases and improve global access to innovative medicines.
Olema Oncology and Aurigene Announce Exclusive Collaboration and License Agreement to Discover and Develop Novel Cancer Therapies
Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA) and Aurigene Discovery Technologies Limited (“Aurigene”) today announced an exclusive global license agreement to research, develop and commercialize novel small molecule inhibitors of an undisclosed oncology target.
Exelixis In-Licenses Second Anti-Cancer Compound from Aurigene Following FDA Acceptance of Investigational New Drug Application for Phase 1 Clinical Trial in Non-Hodgkin’s Lymphoma
Exelixis, Inc. (Nasdaq: EXEL) and Aurigene Discovery Technologies Limited (Aurigene) today announced that Exelixis has exercised its exclusive option under the companies’ July 2019 agreement to in-license XL114
Exelixis and Aurigene Announce That Promising Preclinical Data to Be Presented at the ENA Symposium Support the Clinical Development of a Novel CDK7 Inhibitor
Detailed characterization of an oral inhibitor of CDK7 demonstrates potent activity against multiple hematologic and solid tumor cell lines, as monotherapy and in combination with chemotherapies
Exelixis and Aurigene Enter Into Exclusive Collaboration, Option and License Agreement to Discover and Develop Novel Therapies for Cancer
Companies will partner to advance small molecules in up to six discrete projects, including three existing programs against specific predetermined targets
Phase 1 data from the study expected to be available by December 2018
Curis Announces FDA Fast Track Designation for Fimepinostat (CUDC-907) Development in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Curis, Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the development of fimepinostat in patients with relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy.
Curis Expands Senior Management Expertise with Appointment of Robert Martell, M.D., Ph.D., as Head of Research and Development
Curis, Inc. today announced that Robert Martell, M.D., Ph.D., has been appointed Head of Research and Development.
Aurigene Discovery Technologies Limited, A Wholly Owned Subsidiary Of Dr. Reddy's Laboratories Ltd.’s, And Curis Announce CA-170 Program Update Following Data Presented At ESMO 2017
Curis And Aurigene Discovery Technologies Limited Announce CA-170 Program Update Following Data Presented At ESMO 2017
Agios And Aurigene Discovery Technologies Limited Enter Into Exclusive License Agreement For Novel Small Molecules For Cancer Metabolism Target
Aurigene Discovery Technologies Limited Announces The Exercise Of Curis' Option For CA-327 (PD-L1/TIM-3 Small Molecule Antagonist), The Third Program Under Its Collaboration, License And Option Agreement Of January, 2015 (October 11, 2016, New Jersey, NJ,
Curis And Aurigene Discovery Technologies Limited Present Preclinical Data From Multiple Programs At AACR Annual Meeting
Aurigene Discovery Technologies Limited To Present Its CDK7 And KRAS Covalent Inhibitor Programs At AACR Annual Conference
Aurigene Discovery Technologies Limited To Present Its CDK7, Dual PD-1/VISTA And IRAK4 Inhibitor Programs At AACR-National Cancer Institute-EORTC International Conference On Molecular Targets And Cancer Therapeutics (November 5-9, Boston, MA)
Aurigene Discovery Technologies Limited And Orion Corporation Announce Research, Collaboration And Option Agreement For Rights To Aurigene's Epigenetics Program For Pan BET And Selective BET Bromodomain Inhibitors
Aurigene Discovery Technologies Limited And Pierre Fabre Announce A Licensing Agreement For A New Cancer Therapeutic In Immuno-Oncology : AUNP12, An Immune Checkpoint Modulator Targeting The PD-1 Pathway
Aurigene Discovery Technologies Limited and Debiopharm Group™ Report Nomination of Development Candidate Debio 0617B in Oncology
Aurigene Discovery Technologies Limited and Debiopharm Report Nomination of Development Candidate Debio 0617B in Oncology